Lupin declines after USFDA concludes inspection with two observations at Ankleshwar facility
Lupin is currently trading at Rs. 2288.50, down by 55.95 points or 2.39% from its previous closing of Rs. 2344.45 on the BSE.
The scrip opened at Rs. 2297.40 and has touched a high and low of Rs. 2318.45 and Rs. 2283.00 respectively. So far 19622 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2368.00 on 06-Mar-2026 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2368.00 and Rs. 2256.05 respectively. The current market cap of the company is Rs. 105442.16 crore.
The promoters holding in the company stood at 46.89%, while Institutions and Non-Institutions held 47.07% and 6.03% respectively.
US Food and Drug Administration (USFDA) has concluded an inspection at Lupin’s manufacturing facility at Ankleshwar, India. The Inspection was conducted from March 02, 2026 to March 07, 2026 and closed with the issuance of a Form-483 with two observations. The company will address the observations and respond to the USFDA within the stipulated timeframe.
